Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically- or cytologically- confirmed Non-Small-Cell Lung Cancer~* Stage IIIB/IV~* No prior chemotherapy~* Presence of two-dimensional measurable disease. The measurable disease should not have been irradiated.~* Absence or irradiated and stable central nervous system metastatic disease~* Life expectancy of more than 3 months~* Age ≥ 70 years.~* Performance status (WHO) \< 3~* Patients non-frail according to comprehensive geriatric assessment~* Adequate bone marrow function (Absolute neutrophil count \> 1000/mm\^3, Platelet count \> 100000/mm\^3, Hemoglobin \> 9gr/mm\^3).~* Adequate liver (Bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2mg/dl).~* Adequate cardiac function (LVEF \> 50%).~* Informed consent.~Exclusion Criteria:~* Psychiatric illness or social situation that would preclude study compliance.~* Other concurrent uncontrolled illness.~* Other invasive malignancy within the past 5 years except nonmelanoma skin cancer.~* No presence of a reliable care giver~* Other concurrent investigational agents.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): DG
- 2 (Type: EXPERIMENTAL): G

Based on this trial design, predict the completion outcome and termination type (if applicable).